

ForPatients

by Roche

Relapsing-Remitting Multiple Sclerosis (RRMS) Multiple Sclerosis (MS)

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Trial Status
Completed

Trial Runs In
29 Countries

Trial Identifier
NCT03085810 2016-002937-31
MA30143

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks. The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03085810 2016-002937-31 MA30143
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years & ≤ 55 Years

Healthy Volunteers
No
